Boosting Clinical Cooperation for Improved Efficacy of Clinical Trials

The EU Member States are forming an effective alliance with the European Commission for the execution of clinical trials.  

FREMONT, CA: A centralised pandemic-oriented clinical research response is a highly challenging factor in the EU, in correspondence with its divergent players, healthcare delivery, and clinical systems. Hence, a European pandemic clinical research authority ought to encompass ideas that enable pandemic preparation, clinical research response, and prioritisation of clinical studies. The authorisation should be well-advised by a pan-European board of clinical researchers who are accustomed to conducting trials under disastrous circumstances like pandemics.

An effective partnership between the EU Member States and the European Commission owing to the agreement on enlisted goals during pandemics acquires comprehensive strategies, dedication towards leadership. Alongside, a political commitment with ministers in both the health and research sector also accumulates. Similarly, accumulating pharmaceutical and biotechnology industries in a collaborative measure is another comprehensive technique. Generally, the interpretation of ethics and data protection requirements is often carried out with varying degrees of restrictions as categorised by the local and national control bodies, with the conduct of clinical trials favoured through the harmonisation of law.

However, the inclusion of harmonisation of laws or regulations in member states frequently remains a question with the legally binding acts of the Union that are adopted under the Treaty provisions. They are mainly concerned with the functioning of the EU on public health. Besides, retaining a unification and centralisation response to COVID-19 was likely uncertain with its member states’ reliance on primary sovereignty maintenance. Thus, health remained crucial in a political agenda and thus empowering the reforms accordingly is pivotal.

Trials like RECOVERY and REMAP-CAP are designed to facilitate the integration of clinical research with front-line clinical care and minimise administrative burdens in addition to patient inclusion. These enhanced visions favoured the success of these platform trials despite the tiresome, traditional, and highly complicated clinical approaches involved. Similarly, clinical trial implementation accelerates as a complex and cost-efficient sector with the quality standards for evaluating experimental drugs fluctuating. This is highly due to the evolutions that take place in evaluating repurposed drugs on account of a pandemic. That is, a fluctuation in the probabilities of an on-site initiation visit and data audit persists owing to movement restrictions. Besides, the extensive sources of endpoints are also interrupted via the required speed of data analysis. Therefore, it is critical to rely on defined standards for efficient trial execution, thus coping with the pandemic.